Journal of Neural Transmission

, Volume 75, Issue 2, pp 83–99 | Cite as

Reciprocal interactions between α2-adrenoceptor agonist and neuropeptide Y binding sites in the nucleus tractus solitarius of the rat

A biochemic and autoradiographic analysis
  • A. Härfstrand
  • K. Fuxe
  • L. Agnati
  • B. Fredholm
Original Papers
Received:
Accepted:

Summary

Interactions between a α2-adrenoreceptor agonist and neuropeptide Y (NPY) binding sites have been studied in the rat medulla oblongata (MO) using biochemical binding techniques as well as quantitative autoradiography. Tritiated para-amino clonidine (3H-PAC; α2-adrenoceptor agonist), idazoxan (3H-IDA; α2-adrenoceptor antagonist) and iodinated neuropeptide Y (125I-NPY) were used as radioligands. (1) Neuropeptide Y (NPY; 10−8M) but not bovine pancreatic polypeptide (BPP) nor peptide YY (PYY 10nM) increased the KD value of3H-PAC binding sites. However, intraventricular administration of a high dose of NPY (1.25nmol) did not change the3H-PAC binding characteristics in MO membrane preparations of these animals. (2) GTP 10−4 lowered the affinity of3H-PAC binding. NPY (10 nM) had no additional effect, nor did NPYinfluence the GTP induced shift in potency of clonidine to displace3H-IDA from its binding sites. (3) In the autoradiographical experiments NPY (10nM) significantly reduced3H-PAC binding (2nM) in the nucleus tractus solitarius (NTS) area by 35%. (4) When clonidine, either given centrally in vivo (3.75nmol) or in vitro (10 nM) the binding of125I-NPY was reduced (34 and 24%, respectively) in the NTS. When the monoamine receptors were irreversibly blocked in vivo by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ, 10 μg i.e. 24h)125I-NPY (0.5 nM) binding was increased by 137% in the NTS. This effect of EEDQ was prevented by pretreatment with the α2-adrenoreceptor antagonist idazoxan.

These results provide support for a direct intramembrane interaction between the α2-receptor and the NPY receptor within the NTS and may be of importance in central cardiovascular regulation.

Keywords

Cardiovascular regulation nucleus tractus solitarius receptor-receptor interactions NPY catecholamine GTP rat 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler CH, Meller E, Goldstein M (1985) Recovery of α2-adrenoceptor binding and function after irreversible inactivation by N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Eur J Pharmacol 116: 175–178Google Scholar
  2. Adrian TE, Allen JM, Bloom SR, Ghatei MA, Rossor MN, Roberts GW, Crow TJ, Tatemoto K, Polak JM (1933) Neuropeptide Y distribution in human brain. Nature 306: 584–586Google Scholar
  3. Agnati LF, Fuxe K, Benfenati F, Battistini N, Härfstrand A, Tatemoto K, Hökfelt T, Mutt V (1983 a) Neuropeptide Y in vitro selectively increases the number of α2-adrenergic binding sites in membranes of the medulla oblongata of the rat. Acta Physiol Scand 118: 293–295Google Scholar
  4. Agnati LF, Fuxe K, Benfenati F, Battistini N, Härfstrand A, Hökfelt T, Cavicchioli L, Tatemoto K, Mutt V (1983 b) Failure of neuropeptide Y in vitro to increase the number of binding sites in membranes of the medulla oblongata of the spontaneously hypertensive rat. Acta Physiol Scand 119: 309–312Google Scholar
  5. Agnati LF, Fuxe K, Benfenati F, Zini I, Zoli M, Fabbri L, Härfstrand A (1984) Computer assisted morphometry and microdensitometry of transmitter identified neurons with special reference to the mesostriatal dopamine pathway. I. Methodological aspects. Acta Physiol Scand [Suppl] 532: 5–36Google Scholar
  6. Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, Polak JM (1983) Neuropeptide Y distribution in the rat brain. Science 221: 877–879Google Scholar
  7. Belleau B, Martel R, Lacasse G, Ménard M, Weinberg NL, Perron YG (1968) N-carboxylic acid esters of 1,2- and 1,4-dihydroquinolines. A new class of erreversible inactivators of the catecholamine α receptors and potent central nervous depressants. J Am Chem Soc 90: 823–824Google Scholar
  8. Benfenati F, Cimino M, Agnati LF, Fuxe K (1986) Quantitative autoradiography of central neurotransmitter receptors: methodoligical and statistical aspects with special reference to computerassisted image analysis. Acta Physiol Scand 128: 129–146Google Scholar
  9. Bolme P, Corrodi H, Fuxe K, Hökfelt T, Lidbrink P, Goldstein M (1974) Possible involvement of central adrenaline neurons in vasomotor and respiratory control. Studies with clonidine and its interactions with piperoxane and yohimbine. Eur J Pharmacol 28: 89–94Google Scholar
  10. Boulton AA, Baker GB, Hrdina PD (1986) Neuromethods, vol 4, receptor binding. Humana Press, Clifton, NJGoogle Scholar
  11. Broomé M, Hökfelt T, Terenius L (1985) Peptide YY (PYY)-immunoreactive neurons in the lower brain stem and spinal cord of rat. Acta Physiol Scand 125: 349–352Google Scholar
  12. Changeux JP, Devillers-Thiéry A, Chemouilli P (1984) The acetylcholine receptor: an allosteric protein engaged in intercellular communication. Science 225: 1335–1345Google Scholar
  13. Chapleo CB, Doxey JC, Meyers PL, Roach AG (1981) RX 781094, a new potent, selective antagonist of α2-adrenoreceptors. Br J Pharmacol 74: 842Google Scholar
  14. Chapleo CB, Doxey JC, Meyers PL, Roach H Jr, Yaksh TL (1985) (3H)p-aminoclonidine binding to multiple α2-adrenoceptor sites in homogenates of cat frontal cortex and cat spinal chord. Eur J Pharmacol 106: 547–559Google Scholar
  15. Cummins JT, von Euler G, Fuxe K, Ögren SO, Agnati LF (1987) Chronic imipramine treatment reduces (+)2(125I)iodolysergic acid diethylamide but no125I-neuropeptide Y binding in layer IV of rat cerebral cortex. Neurosci Lett 75: 152–156Google Scholar
  16. Dahlström A, Fuxe K (1964) Evidence for the existence of monoamine containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand [Suppl] 62: 1–55Google Scholar
  17. De Quidt ME, Emson PC (1986) Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system-II. Immunohistochemical analysis. Neuroscience 18: 545–618Google Scholar
  18. Doxey JC, Roach AG, Smith CFC (1983) Studies on RX 781094: a selective, potent and specific antagonist of α2-adrenoceptors. Br J Pharmacol 78: 489–505Google Scholar
  19. Everitt BJ, Hökfelt T, Terenius L, Tatemoto K, Mutt V, Goldstein M (1984) Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. Neuroscience 11: 443–462Google Scholar
  20. Fredholm BB, Jansen I, Edvinsson L (1985) Neuropeptide Y is a potent inhibitor of cAMP accumulation in feline cerebral vessels. Acta Physiol Scand 124: 467–469Google Scholar
  21. Fuxe K (1965) Evidence for the existence of monoamine containing neurons in the central nervous system IV. The distribution of monoamine containing neurons in the central nervous system. Acta Physiol Scand 64 [Suppl] 247: 39–85Google Scholar
  22. Fuxe K, Hökfelt T, Bolme P, Goldstein M, Johansson O, Jonsson G, Lidbrink P, Ljungdahl Å, Sachs C (1975) The topography of central catecholamine pathways in relation to their possible role in blood pressure control. In: Davies DS, Reid JS (eds) Central action of drugs in blood pressure regulation. Pitman Medical, London, pp 8–22Google Scholar
  23. Fuxe K, Agnati L, Härfstrand A, Zini I, Tatemoto K, Merlo Pick E, Hökfelt T, Mutt V, Terenius L (1983 a) Central administration of neuropeptide Y induces hypotension, bradypnea and EEG synchronization in the rat. Acta Physiol Scand 118: 189–192Google Scholar
  24. Fuxe K, Agnati LF, Benfenati F, Celani M, Zini I, Zoli M, Mutt V (1983 b) Evidence for receptor-receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J Neural Transm [Suppl] 18: 165–179Google Scholar
  25. Fuxe K, Calza L, Benfenati F, Zini I, Agnati LF (1983 c) Quantitative autoradiographic localization of (3H)imipramine binding sites in the brain of the rat: Relationship to ascending 5-hydroxytryptamine neuron systems. Proc Natl Acad Sci USA 80: 3836–3840Google Scholar
  26. Fuxe K, Agnati LF, Härfstrand A, Martire M, Goldstein M, Grimaldi R, Bernardi P, Zini I, Tatemoto K, Mutt V (1984) Evidence for a modulation by neuropeptide Y of the α-2 adrenergic transmission line in central adrenaline synapses. New possibilities for treatment of hypertensive disorders. Clin Exp Hypertens [A] 6: 1951–1956Google Scholar
  27. Fuxe K, Agnati LF (1985) Receptor-receptor interactions in the central nervous system. Med Res Rev 5: 441–482Google Scholar
  28. Fuxe K, Agnati LF, Härfstrand A, Zoli M, Janson AM (1985) Image analysis and the determination of codistribution and coexistence of neuroactive substances in nerve terminal populations. Acta Stereol 4: 181–186Google Scholar
  29. Fuxe K, Agnati LF, Härfstrand A, Janson AM, Neumeyer A, Andersson K, Ruggeri M, Zoli M, Goldstein M (1986) Morphofunctional studies on the neuropeptide Y/adrenaline costoring terminal systems in the dorsal cardiovascular region of the medulla oblongata. Focus on receptor-receptor interactions in cotransmission. Prog Brain Res 68: 303–320Google Scholar
  30. Glossmann H, Prasek P (1979) Alpha-noradrenergic receptors in brain membranes: sodium, magnesium and guanyl nucleotides modulate agonist binding. Naunyn Schmiedebergs Arch Pharmacol 306: 67–73Google Scholar
  31. Glossmann H, Hornung R (1980) Alpha2-adrenoceptors in brain: the divalent cation site. Naunyn Schmiedebergs Arch Pharmacol 314: 101–109Google Scholar
  32. Goldstein M, Kusano N, Adler C, Meller E (1986) Characterization of central neuropeptide Y receptor binding sites and possible interactions with α2-adrenoceptors. Prog Brain Res 68: 331–336Google Scholar
  33. Greengard P, Robison GA (1985) Advanced in cyclic nucleotide and protein phosphorylation research. Raven Press, New YorkGoogle Scholar
  34. Hamblin MW, Creese I (1983) Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroxyquinoline. Life Sci 32: 2247–2255Google Scholar
  35. Heller H (1933) Über die zentrale Blutdruckwirkung des Adrenalins. Naunyn Schmiedebergs Arch Exp Pathol 173: 291–300Google Scholar
  36. Hill AV (1909) The mode of action of nicotine and curari determined by the form of the contraction curve and the method of temperature coefficients. J Physiol (Lond) 39: 361–373Google Scholar
  37. Hollander M, Wolfe DA (1973) Nonparametric statistical methods. Wiley, New YorkGoogle Scholar
  38. Härfstrand A, Fuxe K, Agnati LF, Ganten D, Eneroth P, Tatemoto K, Mutt V (1984) Studies on Neuropeptide-Y catecholamine interactions in central cardiovascular regulation in the α-chloralose anaesthetized rat. Evidence for a possible new way of activating the α-2 adrenergic transmission line. Clin Exp Hypertens [A] 6: 1947–1950Google Scholar
  39. Härfstrand A (1986) Intraventricular administration of neuropeptide Y (NPY) induces hypotension, bradycardia and bradypnoea in the awake unrestrained male rat. Counteraction by NPY-induced feeding behaviour. Acta Physiol Scand 128: 121–123Google Scholar
  40. Härfstrand A, Fuxe K, Agnati L, Benfenati F, Goldstein M (1986) Receptor autoradiographical evidence for high densities of125I-Neuropeptide Y binding sites in the nucleus tractus solitaruus of the normal male rat. Acta Physiol Scand 128: 195–200Google Scholar
  41. Härfstrand A (1987) Brain neuropeptide Y mechanisms. Basic aspects and involvement in cardiovascular and neuroendocrine regulation. Acta Physiol Scand 131 [Suppl] 565: 1–83Google Scholar
  42. Härfstrand A, Kalia M, Terenius L, Fuxe K (1987 a) Neuropeptide Y immunoreactive pericarya and nerve terminals in the rat medulla oblongata. Relationship to cytoarchitecture and catecholaminergic cell groups. J Comp Neurol 260: 20–35Google Scholar
  43. Härfstrand A, Fuxe K, Agnati L, Kitayama I, Cintra A, Janson AM, Kalia M, Vanderhaegen JJ, Goldstein M, Terenius L (1987 b) Intracisternal administration of cholecystokinin-8 counteracts the central cardiovascular effects of adrenaline and NPY. A study based on the coexistence of cholecystokinin, phenylethanolamine N-methyltransferase and neuropeptide Y imrminoreactivity in neurons of the nucleus tractus solitarius. Neurochem Int 10: 481–494Google Scholar
  44. Härfstrand A, Fuxe K (1987 c) Simultaneous central administration of adrenaline and neuropeptide Y leads to antagonistic interactions in vasodepressor responses in awake male rats. Acta Physiol Scand 130: 529–531Google Scholar
  45. Härfstrand A, Fredholm B, Fuxe K (1987 c) Inhibitory effects on cyclic AMP accumulation in slices of the nucleus tractus solitarius. Neurosci Lett 76: 185–190Google Scholar
  46. Härfstrand A, Fuxe K, Agnati L, Kitayama I, Cintra A, Janson AM, Kalia M, Vanderhaeghen Goldstein M, Terenius L (1987 a) Intracisternal administration of cholecystokinin-8 counteracts the central cardiovascular effects of adrenaline and NPY. A study based on the coexistence of cholecystokinin, phenylethanolamine N-methyltransferase and neuropeptide Y immunoreactivity in neurons of the nucleus tractus solitarius. Neurochem Int 104: 481–494Google Scholar
  47. Hökfelt T, Fuxe K, Goldstein M, Johansson O (1973) Evidence for adrenaline neurons in the rat brain. Acta Physiol Scand 89: 286–288Google Scholar
  48. Hökfelt T, Fuxe K, Goldstein M, Johansson O (1974) Immunohistochemical evidence for the existence of adrenaline neurons in the rat brain. Brain Res 66: 235–251Google Scholar
  49. Hökfelt T, Lundberg JM, Tatemoto K, Mutt V, Terenius L, Polak J, Bloom S, Sasek Elde R, Goldstein M (1983 a) Neuropeptide Y (NPY) and FMRF amide neuropeptide-like immunoreactivities in catecholamine neurons of the rat medulla oblongata. Acta Physiol Scand 117: 315–318Google Scholar
  50. Hökfelt T, Lundberg JM, Lagerkrantz H, Tatemoto K, Mutt V, Terenius L, Everitt BJ, Fuxe K, Agnati LF, Goldstein M (1983 b) Occurrence of neuropeptide Y (NPY)-like immunoreactivity in catecholamine neurons in human medulla oblongata. Neurosci Lett 36: 217–222Google Scholar
  51. Hökfelt T, Everitt BJ, Fuxe K, Kalia K, Agnati LF, Johansson O, Härfstrand A, Lundberg JM, Terenius L, Theodorsson-Norheim E, Goldstein M (1984 a) Transmitter and peptide systems in areas involved in the control of blood pressure. Clin Exp Hypertens [A] 6: 23–41Google Scholar
  52. Hökfelt T, Johansson O, Goldstein M (1984 b) Central catecholamine neurons as revealed by immunohistochemistry with special reference to adrenaline neurons. In: Björklund A, Hökfelt T (eds) Handbook of chemical neuroanatomy, vol 2, classical transmitters in the CNS. Elsevier, Amsterdam, pp 157–276Google Scholar
  53. Jacobs KH (1985) Coupling mechanisms of α-2 adrenoreceptors. J Cardiovasc Pharmacol 7 [Suppl] 6: 109–112Google Scholar
  54. Kalia M, Sullivan M (1980) Brain stem projections of sensory and motor components of the vagus nerve in the rat. J Comp Neurol 211: 248–264Google Scholar
  55. Kalia M (1981) Localization of aortic and carotid baroreceptor and chemoreceptor primary afferents in the brain stem. In: Buckley JP, Ferrario CM (eds) Central nervous system mechanisms in hypertension. Raven Press, New York, pp 9–24Google Scholar
  56. Kalia M, Fuxe K, Goldstein M (1985 a) Rat medulla oblongata II. Dopaminergic, noradrenergic (A 1 and A 2) and adrenergic neurons, nerve fibers and presumptive terminal prosesses. J Comp Neurol 233: 308–332Google Scholar
  57. Kalia M, Fuxe K, Goldstein M (1985 b) Rat medulla oblongata III. Adrenergic (C1 and C2) neurons, nerve fibers and presumptive terminal processes. J Comp Neurol 233: 333–349Google Scholar
  58. Kassis S, Olasmaa M, Terenius L, Fishmann PH (1987) Neuropeptide Y inhibits cardiac adenylate cyclase through a pertussis toxinsensitive G protein. J Biol Chem 26/8: 3429–3431Google Scholar
  59. Kobinger W (1978) Central α-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol 81: 39–100Google Scholar
  60. Kubo T, Misu Y (1981) Pharmacological characterization of the α-adrenoceptors responsible for a decrease of blood pressure in the nucleus tractus solitarii of the rat. Naunyn Schmiedebergs Arch Pharmacol 317: 120–125Google Scholar
  61. Kuhar MJ, Unnerstall JR (1985) Quantitative receptor mapping by autoradiography: some current technical problems. TINS February: 49–53Google Scholar
  62. Lowry O, Rosenborough N, Farr C, Randall R (1951) Protein measurement with the Folin reagent. J Biol Chem 193: 265–275Google Scholar
  63. Lundberg JM, Hemsén A, Rudehill A, Härfstrand A, Larsson O, Sollevi A, Saria A, Hökfelt T, Fuxe K, Fredholm B (1988) Neuropeptide Y- and alpha-adrenergic receptors in pig spleen: localization, binding characteristics, cyclic AMP effects and functional responses in control and denervated animals. Neuroscience 24: 54–672Google Scholar
  64. Martel JC, St-Pierre S, Qurion R (1986) Neuropeptide Y receptors in rat brain: autoradiographic localization. Peptides 7: 55–60Google Scholar
  65. Martire M, Fuxe K, Pistritto G, Preeziozi P, Agnati LF (1986) Neuropeptide Y enhances the inhibitory effects of clonidine on3H-noradrenaline release in synaptosomes isolated from the medulla oblongata of the male rats. J Neural Transm 67: 113–124Google Scholar
  66. McLaughlin NJ, Collins GGS (1986) Binding characteristics of the selective α2-adrenoceptor antagonist (3H)idazoxan to rat olfactory cortex membranes. Eur J Pharmacol 121: 91–96Google Scholar
  67. Meller E, Bohmaker K, Goldstein M, Friedhoff J (1985) Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics. J Pharmacol Exp Ther 223: 656–662Google Scholar
  68. Mitrus JC, U'Prichard DC (1985) Regulation of α2-adrenoreceptors by nucleotides, ions and agonists: Comparison in cells of neural and nonneural origin. In: Cooper DMF, Seamon KB (eds) Advances in cyclic nucleotide and protein phosphorylation research, vol 19. Raven Press, New York, pp 57–73Google Scholar
  69. Miura M, Reis DJ (1969) Termination and secondary projection of carotid sinus nerve in cat brain stem. Am J Physiol 217: 142–153Google Scholar
  70. Mooney JJ, Horne WC, Handin RI, Schildkraut JJ, Alexander RW (1982) Sodium inhibits both adenylate cyclase and high-affinity3H-labeled p-aminoclonidine binding to alpha2-adrenergic receptors in purified human platelet membranes. Mol Pharmacol 21: 600–608Google Scholar
  71. Munson PJ (1983) Ligand. A computerized analysis of ligand binding data. In: Langer J, van Vunahis H (eds) Methods in enzymology, vol 92. Academic Press, New York, pp 543–576Google Scholar
  72. Nakajima T, Yashima Y, Nakamura K (1986) Quantitative autoradiographic localization of neuropeptide Y receptors in the rat lower brainstem. Brain Res 380: 144–150Google Scholar
  73. Olasmaa M, Terenius L (1986) Neuropeptide Y receptor interaction with α-adrenoceptor coupling to adenylate cyclase. Prog Brain Res 68: 337–341Google Scholar
  74. Rodbell M (1980) The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature 284: 17–22Google Scholar
  75. Rodbell M, Krans HM, Pohl SL, Birnbaumer L (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. IV. Effects of guanylnucleotides on binding of125I-glucagon. J Biol Chem 246: 1872–1876Google Scholar
  76. Rouot B, Snyder SH (1979)3H-para amino-clonidine: A novel ligand which binds with high affinity to α-adrenergic receptors. Life Sci 25: 769–774Google Scholar
  77. Rouot B, Quennedy MC, Schwartz J (1982) Characteristics of the3H-yohimbine binding on rat brain α2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 321: 253Google Scholar
  78. Saria A, Theodorsson-Norheim E, Lundberg JM (1984) Evidence for specific neuropeptide Y-binding sites in rat brain synaptosomes. Eur J Pharmacol 107: 105–107Google Scholar
  79. Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672Google Scholar
  80. Snedecor GW, Cochran WG (1980) Statistical methods, 7th edn. The Iowa State University Press, Ames, IowaGoogle Scholar
  81. Tatemoto K (1982 a) Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci USA 79: 2514–2518Google Scholar
  82. Tatemoto K (1982 b) Neuropeptide Y. Complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA 79: 5484–5489Google Scholar
  83. Tatemoto K, Carlquist M, Mutt V (1982) Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 269: 659–660Google Scholar
  84. Undén A, Tatemoto K, Mutt V, Bartfai T (1984) Neuropeptide Y receptor in the rat brain. Eur J Biochem 145: 525–530Google Scholar
  85. Undén A, Bartfai T (1984) Regulation of neuropeptide Y binding by guanine nucleotides in the rat cerebral cortex. FEBS Lett 177: 125–128Google Scholar
  86. Westlind-Danielsson A, Undén A, Abens J, Andell S, Bartfai T (1987) Neuropeptide Y and the inhibition of adenylate cyclase in the human frontal and temporal cortex. Neurosci Lett 74: 237–242Google Scholar
  87. Williams LT, Lefkowitz RJ (1978) Receptor binding studies in adrenergic pharmacology. Raven Press, New YorkGoogle Scholar
  88. Young WS, Kuhar MJ (1979) Noradrenergic α 1 and α 2 receptors: autoradiographic visualization. Eur J Pharmacol 59: 317–319Google Scholar
  89. Young WS III, Kuhar MJ (1980) Noradrenergic alpha-1 and alpha-2 receptors: light microscopic autoradiographic localization. Proc Natl Acad Sci USA 77: 1696–1700Google Scholar
  90. Zandberg P, De Jong W, De Wied (1979) Effect of catecholamina-receptor stimulating agents on blood pressure after local application in the nucleus tractus solitarii of the medulla oblongata. Eur J Pharmacol 55: 43–56Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • A. Härfstrand
    • 1
  • K. Fuxe
    • 1
  • L. Agnati
    • 2
  • B. Fredholm
    • 3
  1. 1.Department of Histology and NeurobiologyKarolinska InstitutetStockholmSweden
  2. 2.Department of Human PhysiologyUniversity of ModenaModenaItaly
  3. 3.Department of PharmacologyKarolinska InstitutetStockholmSweden

Personalised recommendations